Getinge 2022 Annual Report

Getinge 2022 Annual Report OFFERING FROM A CUSTOMER PERSPECTIVE Products Introduction Strategy Corporate Governance Annual Report Sustainability Report Other information Contents Intensive Care Life supporting therapies for intensive care, in the form of ventilators, hemodynamic monitoring and ECMO. 60% Cardiovascular Surgery Products for advanced cardiac surgery, such as heart-lung machines, heater-cooler units, beating heart surgery, endoscopic vessel harvesting, left atrial appendage closure devices, anesthesia systems, aortic and peripheral vascular grafts and thoracic drainage systems. 26% Cardiovascular Interventions Products to facilitate cardiovascular procedures, such as products for cardiac assist and peripheral vascular stents. 14% Getinge's addressable market amounts to SEK 100 billion with anticipated organic growth of 4-6% per year. Share of sales within Acute Care Therapies (average 3 years) Market growth per year 4-6% Getinge's position 1 Getinge's market share 30-35% 1-2% 1 20-25% Main competitors Dräger, Hamilton, Medtronic, Edwards Lifesciences LivaNova, Terumo, GE Healthcare, Dräger, WL Gore, Medtronic Business area's share of Group sales Acute Care Therapies, 54% 3-5% 5 5-10% WL Gore, Medtronic, Boston Scientific, Abbott, Cook, BD Business area's regional distribution of sales Net sales and adjusted EBITA margin MSEK 25,000 % 50 Americas, 50% (SEK 7,624 M) 20,000 40 15,000 30 Net sales EMEA, 27% (SEK 4,151 M) 10,000 20 Adjusted EBITA margin APAC, 23% (SEK 3,510 M) 5,000 10 0 0 2021 2022 19

View entire presentation